Oxford Biodynamics PLC (OBD) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Oxford Biodynamics PLC (OBD) has a cash flow conversion efficiency ratio of -2.475x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (GBX-2.76 Million ≈ $-336.06 USD) by net assets (GBX1.12 Million ≈ $135.78 USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Oxford Biodynamics PLC (OBD) balance sheet quality index to measure how much of total assets are equity-financed.
Oxford Biodynamics PLC - Cash Flow Conversion Efficiency Trend (2013–2025)
This chart illustrates how Oxford Biodynamics PLC's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check total reinvestment intensity of Oxford Biodynamics PLC to assess the company's total reinvestment commitment from operating cash flow.
Oxford Biodynamics PLC Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Oxford Biodynamics PLC ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Fadel Partners Inc
LSE:FADL
|
N/A |
|
Serinus Energy
LSE:SENX
|
0.002x |
|
Tiger Royalties and investments Plc
LSE:TIR
|
-0.272x |
|
Amur Minerals Corporation
LSE:CRTX
|
-0.663x |
|
Philipp Holzmann AG
DU:HOZ
|
N/A |
|
Harmony Energy Income Trust PLC
LSE:HEIT
|
0.003x |
|
Bisichi Mining PLC
LSE:BISI
|
0.027x |
|
MOLECULE HOLDINGS
F:ERV2
|
N/A |
Annual Cash Flow Conversion Efficiency for Oxford Biodynamics PLC (2013–2025)
The table below shows the annual cash flow conversion efficiency of Oxford Biodynamics PLC from 2013 to 2025. For the full company profile with market capitalisation and key ratios, see OBD stock market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-09-30 | GBX1.12 Million ≈ $135.78 |
GBX-7.71 Million ≈ $-937.96 |
-6.908x | -195.95% |
| 2024-09-30 | GBX4.36 Million ≈ $530.24 |
GBX-10.17 Million ≈ $-1.24K |
-2.334x | -67.53% |
| 2023-09-30 | GBX6.05 Million ≈ $736.72 |
GBX-8.44 Million ≈ $-1.03K |
-1.393x | +30.35% |
| 2022-09-30 | GBX2.59 Million ≈ $314.88 |
GBX-5.18 Million ≈ $-629.89 |
-2.000x | -126.23% |
| 2021-09-30 | GBX6.69 Million ≈ $814.34 |
GBX-5.92 Million ≈ $-720.05 |
-0.884x | -253.08% |
| 2020-09-30 | GBX13.58 Million ≈ $1.65K |
GBX-3.40 Million ≈ $-413.80 |
-0.250x | -94.01% |
| 2019-09-30 | GBX17.59 Million ≈ $2.14K |
GBX-2.27 Million ≈ $-276.32 |
-0.129x | -33.26% |
| 2018-09-30 | GBX20.05 Million ≈ $2.44K |
GBX-1.94 Million ≈ $-236.29 |
-0.097x | +26.40% |
| 2017-09-30 | GBX11.60 Million ≈ $1.41K |
GBX-1.53 Million ≈ $-185.67 |
-0.132x | +24.40% |
| 2016-09-30 | GBX7.74 Million ≈ $942.10 |
GBX-1.35 Million ≈ $-164.01 |
-0.174x | -28.08% |
| 2015-09-30 | GBX9.04 Million ≈ $1.10K |
GBX-1.23 Million ≈ $-149.53 |
-0.136x | -67.82% |
| 2014-09-30 | GBX5.24 Million ≈ $636.95 |
GBX-424.00K ≈ $-51.59 |
-0.081x | -225.24% |
| 2013-09-30 | GBX2.94 Million ≈ $357.47 |
GBX190.00K ≈ $23.12 |
0.065x | -- |
About Oxford Biodynamics PLC
Oxford BioDynamics Plc, together with its subsidiaries, operates as a biotechnology company that y developing, and commercializing precision medicine tests for life-changing diseases in the United States and the United Kingdom. The company provides EpiSwitch CiRT (Checkpoint inhibitor Response Test), a blood test that predicts an individual patient's therapeutic response to checkpoint inhibitor i… Read more